Título: Analysis of the use of Probiotics and Synbiotics in the treatment of irritable bowel syndrome
Título alternativo: Analysis of the use of Probiotics and Synbiotics in the treatment of irritable bowel syndrome
Autoria de: Pedro Ribeiro Rosario
Orientação de: Sarah Leao Fiorini de Aguiar
Presidente da banca: Sarah Leao Fiorini de Aguiar
Primeiro membro da banca: Ivina Catarina de Oliveira Guimaraes
Segundo membro da banca: Dirceu de Sousa Melo
Terceiro membro da banca: Leandra Passarelli Castro de Souza
Palavras-chaves: Microbiota, Irritable Bowel Syndrome, Probiotics, synbiotics, Gut-Brain
Data da defesa: 08/06/2026
Semestre letivo da defesa: 2026-1
Data da versão final: 09/06/2026
Data da publicação: 09/06/2026
Referência: Rosario, P. R. Analysis of the use of Probiotics and Synbiotics in the treatment of irritable bowel syndrome. 2026. 21 p. Trabalho de Conclusão de Curso (Graduação em Nutrição Bacharelado)-Universidade Federal de Lavras, Lavras, 2026.
Resumo: Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder of unknown origin, characterized by frequent symptoms of diarrhea or constipation associated with abdominal bloating and pain. Currently, The prevalence of IBS varies considerably across different geographic regions, with estimates ranging from 25.3 to 32.9 in the general population, indicating a significant impact on public health worldwide. It is also known that several factors are associated with the onset of flare-ups, including increased intestinal permeability, low-grade inflammation, and psychological factors such as stress, anxiety, or depression. In this literature review, some strains have been shown to be effective in controlling symptoms, indicating that the use of probiotics and synbiotics can be part of an appropriate treatment regimen.BackgroundObjectivesThe objective of this study was to conduct a narrative review of the literature on the use of probiotics and synbiotics for symptom management in patients with irritable bowel syndrome, using a major reference database such as PubMed. MethodsThis is a narrative review of the literature. To this end, a search was conducted in the PubMed database, and the current guidelines from the World Gastroenterology Organisation on the use of probiotics, synbiotics, and prebiotics were utilized. For the PubMed search, the following search terms were used ??Microbiota,?? ??Irritable Bowel Syndrome,?? ??Probiotics,?? ??Synbiotics,?? ??Gut-Brain,?? and ??Visceral Hypersensitivity,?? either combined or not with the Boolean operator AND. The search for articles included systematic reviews, meta-analyses of double-blind trials, clinical trials, original studies, and article reviews from the past six years (2020??2026) in order to analyze the most recent articles of the current decade that addressed the use of probiotics or synbiotics and their relationship with the microbiota in the treatment of irritable bowel syndrome and that had an impact factor above 2.9 , as evaluated by the Journal Citation Reports (Clarivate) system,to avoid potential predatory journals.Results The clinical trials reviewed demonstrated that the probiotic and synbiotic combinations of Lactococcus latis LI-23, L. helveticus SP 27, B. Longum BI-05, B. breve Bb-03, Lacticaseibacillus rhamnosus Lr-32, S. thermophiles ST-21, L. casei??LC 11, Lactiplantibacillus plantarum LP-115, and B. Bifidum Bb-02 the combination of Lactobacillus, Bifidobacterium, and Streptococcus thermophilus the combination of L. acidophilus NCFM and L. acidophilus subsp. helveticus LAFTI L10 Lactobacillus paracasei DKGF1 and Opuntia humifus the mixture of Lactobacillus acidophilus CUL60, Lactobacillus acidophilus CUL21 (NCIMB 30156), Bifidobacterium bifidum CUL20 (NCIMB 30153), and B. animalis subsp. lactis CUL34. L. acidophilus DDS-1, Bifidobacterium lactis UABla-12 Bifidobacterium longum (BL) NCC3001, and finally Lacticaseibacillus rhamnosus IDCC 3201, were able to improve symptoms in patients with IBS, reduce the intensity of abdominal pain, improve overall symptoms, and regulate the frequency and consistency of bowel movements.Conclusions The use of probiotics and synbiotics may be part of a treatment strategy for irritable bowel syndrome, as they act on intestinal pathophysiological and regulatory mechanisms however, further studies are needed using different strains and standardized dosages and intervention durations.
Abstract: Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder of unknown origin, characterized by frequent symptoms of diarrhea or constipation associated with abdominal bloating and pain. Currently, The prevalence of IBS varies considerably across different geographic regions, with estimates ranging from 25.3 to 32.9 in the general population, indicating a significant impact on public health worldwide. It is also known that several factors are associated with the onset of flare-ups, including increased intestinal permeability, low-grade inflammation, and psychological factors such as stress, anxiety, or depression. In this literature review, some strains have been shown to be effective in controlling symptoms, indicating that the use of probiotics and synbiotics can be part of an appropriate treatment regimen.BackgroundObjectivesThe objective of this study was to conduct a narrative review of the literature on the use of probiotics and synbiotics for symptom management in patients with irritable bowel syndrome, using a major reference database such as PubMed. MethodsThis is a narrative review of the literature. To this end, a search was conducted in the PubMed database, and the current guidelines from the World Gastroenterology Organisation on the use of probiotics, synbiotics, and prebiotics were utilized. For the PubMed search, the following search terms were used ??Microbiota,?? ??Irritable Bowel Syndrome,?? ??Probiotics,?? ??Synbiotics,?? ??Gut-Brain,?? and ??Visceral Hypersensitivity,?? either combined or not with the Boolean operator AND. The search for articles included systematic reviews, meta-analyses of double-blind trials, clinical trials, original studies, and article reviews from the past six years (2020??2026) in order to analyze the most recent articles of the current decade that addressed the use of probiotics or synbiotics and their relationship with the microbiota in the treatment of irritable bowel syndrome and that had an impact factor above 2.9 , as evaluated by the Journal Citation Reports (Clarivate) system,to avoid potential predatory journals.Results The clinical trials reviewed demonstrated that the probiotic and synbiotic combinations of Lactococcus latis LI-23, L. helveticus SP 27, B. Longum BI-05, B. breve Bb-03, Lacticaseibacillus rhamnosus Lr-32, S. thermophiles ST-21, L. casei??LC 11, Lactiplantibacillus plantarum LP-115, and B. Bifidum Bb-02 the combination of Lactobacillus, Bifidobacterium, and Streptococcus thermophilus the combination of L. acidophilus NCFM and L. acidophilus subsp. helveticus LAFTI L10 Lactobacillus paracasei DKGF1 and Opuntia humifus the mixture of Lactobacillus acidophilus CUL60, Lactobacillus acidophilus CUL21 (NCIMB 30156), Bifidobacterium bifidum CUL20 (NCIMB 30153), and B. animalis subsp. lactis CUL34. L. acidophilus DDS-1, Bifidobacterium lactis UABla-12 Bifidobacterium longum (BL) NCC3001, and finally Lacticaseibacillus rhamnosus IDCC 3201, were able to improve symptoms in patients with IBS, reduce the intensity of abdominal pain, improve overall symptoms, and regulate the frequency and consistency of bowel movements.Conclusions The use of probiotics and synbiotics may be part of a treatment strategy for irritable bowel syndrome, as they act on intestinal pathophysiological and regulatory mechanisms however, further studies are needed using different strains and standardized dosages and intervention durations.
URI alternaviva: sem URI do Repositório Institucional da UFLA até o momento.
Curso: G023 - NUTRIÇÃO (BACHARELADO)
Nome da editora: Universidade Federal de Lavras
Sigla da editora: UFLA
País da editora: Brasil
Gênero textual: Trabalho de Conclusão de Curso
Nome da língua do conteúdo: Inglês
Código da língua do conteúdo: eng
Licença de acesso: Acesso aberto
Nome da licença: Licença do Repositório Institucional da Universidade Federal de Lavras
URI da licença: repositorio.ufla.br
Termos da licença: Acesso aos termos da licença em repositorio.ufla.br
Detentores dos direitos autorais: Pedro Ribeiro Rosario e Universidade Federal de Lavras
Baixar arquivo